BioWorld

April 23, 2010

View Archived Issues

Transient Receptor Potential Channels Keep Branching Out

Aragon Raises $22M to Move 2 Cancer Drugs Into the Clinic

Earnings Roundup

Stock Movers

Clinic Roundup

Other News To Note

After Mixed Phase III, Alimera Prices $72M IPO Below Range

Four months after delivering mixed Phase III data on diabetic macular edema drug Iluvien, Alimera Sciences Inc. raised $72.1 million in its initial public offering. (BioWorld Today) Read More

Amgen Boasts Solid Quarter; Prolia Launch on the Horizon

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Woman taking medication for mental illness

Sumitomo’s DSP-3456 exerts antidepressant-like effects

BioWorld Science

About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...